Interventions Testing Program
An NIH-funded program run out of three independent labs, considered the most robust scientific tool for testing exogenous molecules for lifespan extension in non-inbred mice; found no benefit for NR or resveratrol.
Common Themes
Videos Mentioning Interventions Testing Program
Journal Club with Dr. Peter Attia | Metformin for Longevity & The Power of Belief Effects
Andrew Huberman
A highly rigorous, NIH-funded program that tests molecules for geroprotective effects in animals, using large sample sizes and multiple labs.
#123–Joan Mannick & Nir Barzilai: Rapamycin and metformin—longevity, immune enhancement, & COVID-19
Peter Attia MD
A rigorous, multi-site program established by the NIH to test drugs for their effects on longevity in genetically heterogeneous animals.
Dr. Peter Attia — Longevity Drugs, Alzheimer's Disease, and More
Tim Ferriss
An NIH-funded program that rigorously tests molecules believed to enhance longevity in small animals, using specialized mice to ensure greater applicability to humans.
#148 - Richard Miller, M.D., Ph.D.: The gold standard for testing longevity drugs: the ITP
Peter Attia MD
A set of rigorous, multi-site studies funded by the NIA to test potential longevity-extending molecules in genetically heterogeneous mice, considered the 'gold standard' for longevity drug testing.
Supplements for Longevity & Their Efficacy | Dr. Peter Attia
Andrew Huberman
An NIH-funded program run out of three independent labs, considered the most robust scientific tool for testing exogenous molecules for lifespan extension in non-inbred mice; found no benefit for NR or resveratrol.
222 ‒ How nutrition impacts longevity | Matt Kaeberlein, Ph.D.
Peter Attia MD
A program started by the NIA (National Institute on Aging) in the early 2000s to test interventions for lifespan extension in mice at three different sites.
204 - Centenarians, metformin, and longevity | Nir Barzilai, M.D.
Peter Attia MD
A highly rigorous study conducted in mice, independently across three labs, known for its all-cause mortality endpoint. Metformin alone did not show strong longevity benefits in ITP, raising questions about species differences or dosing.